Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 11/20 | 0.47 |
| ▸ | MMP3 | P08254 | 8/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP12 | P39900 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10079222 | 0.86 | CYP3A4 (0.55) | HPGD | |
| SCHEMBL8778403 | 0.79 | PRSS1 (0.47) | TSHRMMP2MMP3SMN1; SMN2MEN1 | |
| SCHEMBL10060251 | 0.76 | ANPEP (0.47) | TSHRMMP2MMP3SMN1; SMN2MEN1 | |
| SCHEMBL12899397 | 0.75 | NPC1 (0.58) | TSHRMEN1KMT2AMMP8 | |
| SCHEMBL18814896 | 0.72 | MME (0.61) | MMP2MMP13MMP12 | |
| SCHEMBL14417688 | 0.72 | TSHR (0.49) | TSHRSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL12899400 | 0.72 | KMT2A (0.72) | SMN1; SMN2KMT2AHPGDMMP8 | |
| SCHEMBL15468320 | 0.72 | CYP3A4 (0.43) | MMP2HPGDMMP8 | |
| SCHEMBL10565756 | 0.72 | MEN1 (0.46) | TSHRMEN1KMT2A | |
| SCHEMBL10565751 | 0.72 | MEN1 (0.46) | TSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-8163792-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-04-24 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | TSHR 3389/4885MMP2 2457/4885MMP3 3272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.